# A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

> **NCT02363400** · PHASE3 · TERMINATED · sponsor: **National Health Research Institutes, Taiwan** · enrollment: 10 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** MEP

## Key facts

- **NCT ID:** NCT02363400
- **Lead sponsor:** National Health Research Institutes, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12-14
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Recruiting progress behind expectation
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02363400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02363400, "A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT02363400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*